Cencora, Inc. (NYSE:COR) Shares Bought by Cozad Asset Management Inc.

Cozad Asset Management Inc. lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 64.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,815 shares of the company’s stock after purchasing an additional 1,490 shares during the period. Cozad Asset Management Inc.’s holdings in Cencora were worth $857,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of COR. JFS Wealth Advisors LLC lifted its position in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora in the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after acquiring an additional 69 shares in the last quarter. Kentucky Trust Co bought a new position in Cencora during the 4th quarter valued at $33,000. Finally, WASHINGTON TRUST Co boosted its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares of the company’s stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,648 shares of company stock worth $3,382,462 over the last ninety days. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $260.98 on Tuesday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $263.70. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The business’s 50 day moving average is $248.23 and its 200-day moving average is $239.31. The firm has a market capitalization of $50.61 billion, a PE ratio of 37.12, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.84%. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

COR has been the topic of several research reports. Wells Fargo & Company upped their price target on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a report on Friday. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.